Cargando…

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ

BACKGROUND: Stage 2 hypertension often requires combination antihypertensive therapy. Ambulatory blood pressure monitoring (ABPM) is a useful tool for assessing antihypertensive drugs and their combinations. OBJECTIVE: To compare the effect of a moderate dose of angiotensin receptor blocker/calcium...

Descripción completa

Detalles Bibliográficos
Autores principales: Duprez, Daniel, Ferdinand, Keith, Purkayastha, Das, Samuel, Rita, Wright, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237099/
https://www.ncbi.nlm.nih.gov/pubmed/22174580
http://dx.doi.org/10.2147/VHRM.S25743
_version_ 1782218840262836224
author Duprez, Daniel
Ferdinand, Keith
Purkayastha, Das
Samuel, Rita
Wright, Richard
author_facet Duprez, Daniel
Ferdinand, Keith
Purkayastha, Das
Samuel, Rita
Wright, Richard
author_sort Duprez, Daniel
collection PubMed
description BACKGROUND: Stage 2 hypertension often requires combination antihypertensive therapy. Ambulatory blood pressure monitoring (ABPM) is a useful tool for assessing antihypertensive drugs and their combinations. OBJECTIVE: To compare the effect of a moderate dose of angiotensin receptor blocker/calcium channel blocker (ARB/CCB) combined with a diuretic versus a maximal dose of ARB with a diuretic on 24-hour ambulatory blood pressure monitoring (ABPM) and other derived ambulatory blood pressure (ABP) parameters. METHODS: The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg (n = 48) or losartan 100 mg (n = 36). At week 3, hydrochlorothiazide (HCTZ) 25 mg was added in both treatment groups. ABP was measured at baseline and at week 6. Additionaly, 24-hour ABP, nighttime (10 pm to 6 am) and daytime (6 am to 10 pm) ABP, and ABP load (percentage of readings above 140/90 mmHg) were determined. RESULTS: Eighty-four patients (48 ARB/CCB/HCTZ, 36 ARB/HCTZ) had ABPM at baseline and at week 6. Reductions of systolic/diastolic ABP were greater in the ARB/CCB/ HCTZ group than in the ARB/HCTZ group for 24-hour mean ABP (−22.0/−13.3 versus −17.4/−8.1 mmHg), as well as nighttime ABP (−22.2/−13.3 versus −16.2/−7.4 mmHg), daytime ABP (−21.9/−13.0 versus −18.1/−8.6 mmHg), ABP in the last 4 hours of the dosing period (−21.5/−13.5 versus −17.0/−7.7 mmHg), and ABP load (21.7%/12.8% versus 30.8%/20.0%). CONCLUSION: Initiating antihypertensive treatment with moderate doses of ARB/CCB with a diuretic is more effective in lowering nighttime and daytime ABP and reducing ABP load than a maximal dose of an ARB with a diuretic.
format Online
Article
Text
id pubmed-3237099
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32370992011-12-15 Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ Duprez, Daniel Ferdinand, Keith Purkayastha, Das Samuel, Rita Wright, Richard Vasc Health Risk Manag Original Research BACKGROUND: Stage 2 hypertension often requires combination antihypertensive therapy. Ambulatory blood pressure monitoring (ABPM) is a useful tool for assessing antihypertensive drugs and their combinations. OBJECTIVE: To compare the effect of a moderate dose of angiotensin receptor blocker/calcium channel blocker (ARB/CCB) combined with a diuretic versus a maximal dose of ARB with a diuretic on 24-hour ambulatory blood pressure monitoring (ABPM) and other derived ambulatory blood pressure (ABP) parameters. METHODS: The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg (n = 48) or losartan 100 mg (n = 36). At week 3, hydrochlorothiazide (HCTZ) 25 mg was added in both treatment groups. ABP was measured at baseline and at week 6. Additionaly, 24-hour ABP, nighttime (10 pm to 6 am) and daytime (6 am to 10 pm) ABP, and ABP load (percentage of readings above 140/90 mmHg) were determined. RESULTS: Eighty-four patients (48 ARB/CCB/HCTZ, 36 ARB/HCTZ) had ABPM at baseline and at week 6. Reductions of systolic/diastolic ABP were greater in the ARB/CCB/ HCTZ group than in the ARB/HCTZ group for 24-hour mean ABP (−22.0/−13.3 versus −17.4/−8.1 mmHg), as well as nighttime ABP (−22.2/−13.3 versus −16.2/−7.4 mmHg), daytime ABP (−21.9/−13.0 versus −18.1/−8.6 mmHg), ABP in the last 4 hours of the dosing period (−21.5/−13.5 versus −17.0/−7.7 mmHg), and ABP load (21.7%/12.8% versus 30.8%/20.0%). CONCLUSION: Initiating antihypertensive treatment with moderate doses of ARB/CCB with a diuretic is more effective in lowering nighttime and daytime ABP and reducing ABP load than a maximal dose of an ARB with a diuretic. Dove Medical Press 2011 2011-11-24 /pmc/articles/PMC3237099/ /pubmed/22174580 http://dx.doi.org/10.2147/VHRM.S25743 Text en © 2011 Duprez et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Duprez, Daniel
Ferdinand, Keith
Purkayastha, Das
Samuel, Rita
Wright, Richard
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
title Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
title_full Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
title_fullStr Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
title_full_unstemmed Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
title_short Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
title_sort ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (arb), calcium-channel blocker (ccb), and hctz versus dual therapy with an arb and hctz
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237099/
https://www.ncbi.nlm.nih.gov/pubmed/22174580
http://dx.doi.org/10.2147/VHRM.S25743
work_keys_str_mv AT duprezdaniel ambulatorybloodpressureresponsetotripletherapywithanangiotensinreceptorblockerarbcalciumchannelblockerccbandhctzversusdualtherapywithanarbandhctz
AT ferdinandkeith ambulatorybloodpressureresponsetotripletherapywithanangiotensinreceptorblockerarbcalciumchannelblockerccbandhctzversusdualtherapywithanarbandhctz
AT purkayasthadas ambulatorybloodpressureresponsetotripletherapywithanangiotensinreceptorblockerarbcalciumchannelblockerccbandhctzversusdualtherapywithanarbandhctz
AT samuelrita ambulatorybloodpressureresponsetotripletherapywithanangiotensinreceptorblockerarbcalciumchannelblockerccbandhctzversusdualtherapywithanarbandhctz
AT wrightrichard ambulatorybloodpressureresponsetotripletherapywithanangiotensinreceptorblockerarbcalciumchannelblockerccbandhctzversusdualtherapywithanarbandhctz